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Abstract
Objective: To test cell penetrating and interfering peptide Mut3DPT-PP2A/SET in interaction between serine threonine phosphatase 
PP2A and its physiological inhibitor, the oncoprotein SET.
Materials and methods: Adult male C3H/S-strain mice, 60 days old, were given a graft of breast adenocarcinoma cells (TN60) into 
subcutaneous tissue. Mut3DPT-PP2A/SET peptide was used to block PP2A and SET oncoprotein interaction. The graft-bearing animals 
were divided into a control group (injected with saline buffer), and an intervention group injected intraperitoneally with Mut3DPT-
PP2A/SET peptide (5 mg/kg) every day from day 5 to day 37. The variables we used to compare the outcome in both groups were tumor 
size in mm (length×width) and histological changes. In the statistical analysis we used ANOVA and Student-Keuls multiple compari-
sons test and Tuckey for the post-test analysis.
Results: 48 mice were grafted at day 0 with breast UNLP-C3H/S tumor cells, and after randomization, they were assigned to one of the 
two study groups. At day 5 all mice were injected either with placebo or with the peptide. The treated group showed significant tumor 
reduction (p<0.07). Histological changes showed presence of apoptosis and necrosis of tumor in treated group.
Conclusion: The peptide Mut3DPT-PP2A/SET has demonstrated anti-tumor activity by reduction in vivo of tumor growth becoming 
a promising future in anticancer therapy. 
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INTRODUCTION
Breast cancer is still a major public health problem world-
wide and still poses significant challenges in relation to 
therapeutic options. Breast cancers are characterized by 
uncontrolled growth of malignant cells in the mammary 
epithelial tissue. From the surgical resection introduced in 
the 18th century to novel options including hormonal, che-
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motherapies and targeted drugs to certain cell’s molecules 
like trastuzumab, many treatment alternatives have been 
developed in order to control this disease. However, breast 
neoplasms still remain as one of the leading challenges for 
public health, the most frequent cancer and unfortunately 
one of the major causes of decease in females of the 21st 
century. This fact requires actions to investigate new op-
tions tending to have new therapeutic options to treat this 
disease.
The protein phosphatase 2A (PP2A), one of the main ser-
ine-threonine phosphatases in mammalian cells, maintains 
cell homoeostasis by counteracting most of the kinase-driv-
en intracellular signalling pathways.1 PP2A has been shown 
to be genetically altered or functionally inactivated in many 
solid cancers and leukaemias, characterised by aberrant ac-
tivity of oncogenic kinases. Inhibition of PP2A activity is 
critical to promote cell transformation, tumor progression 
and angiogenesis, which indicates that PP2A has tumor 
suppressive role.2-4 
Recent reports show that pharmacological restoration 
of PP2A tumor-suppressor activity effectively antagonises 
cancer development and progression.4 
SET is a multitask oncoprotein that is critically involved 
in the initiation and progression of cancer cells. Over-ex-
pression of SET protein is a recurrent and clinically relevant 
event in many malignant diseases. SET is over-expressed in 
97% of head and neck squamous cell carcinoma, in more 
than 90% of non-small cell lung cancer (NSCLC, associated 
with worse progression-free survival and overall survival), 
in 70.9% of colon cancer, in 60% of breast tumor tissues 
(regardless of known biological subtypes), and in 47.5% of 
prostate cancer among others. It was shown that the func-
tional inactivation of PP2A was essential for BCR/ABL 
leukemogenesis and, required for blastic transformation in 
chronic myeloid leukaemia (CML).5 
SET has also a critical role in promoting the development 
of therapeutic resistance and, therefore, may be a biomark-
er that predicts drug sensitivity and a therapeutic target to 
enhance current anticancer treatments.6 The SET protein 
binds to PP2A and is a potent physiological inhibitor of 
PP2A phosphatase activity PP2A.7 Accumulation of SET in 
cancer cells, especially haematological cancers, accounts for 
decreased PP2A activity.8,9 
Through direct association, SET affects the function of 
its interacting proteins, such as PP2A inducing the appear-
ance of tumor phenotype.7 Consequently, targeting and 
disrupting the SET-PP2A interaction would result in a re-
covered PP2A activity and reduced tumor activity. Recent 
data have shown that antagonizing SET restores sensitivity 
to anticancer effects of chemotherapies of previously resis-
tant models. Three novel compounds, the small molecules 
FTY720 (Fingolimod, Gilenya) and EMQA (TD-x series), 
and the apolipoprotein-E mimetic peptides (COG112, 
OP449), targeting the SET-PP2Ac interface inhibit tumor 
growth and overcome therapeutic resistance in many dif-
ferent malignant diseases. We have experimentally identi-
fied the sequence of PP2A binding to SET using a PEP-scan 
approach.10 This sequence is exposed at the surface of the 
protein PP2A and is associated to a cell penetrating peptide 
in order to generate the peptide Mut3DPT-PP2A/SET. 
The peptide Mut3DPT-PP2A/SET has been tested 
chronic lymphocytic leukemia xenograft models showing 
an increase in the survival of the mice. In order to prove the 
activity of the peptide Mut3DPT-PP2A/SET against aggres-
sive breast cancer cells, we performed the present prelimi-
nary study in a breast cancer xenograft model developed in 
our laboratory (Histology A, School of Medicine, National 
University of La Plata).11 The chimeric peptide blocking 
PP2A/SET interactions showed an important tumor growth 
inhibition, suggesting that it can be used as therapeutic tool 
for breast cancer treatment.
MATERIALS AND METHODS
Mice: adult male C3H/S-strain mice of 60 days of age raised 
in the bioterium of Cytology, Histology and Embryology 
“A” of the Faculty of Medical Sciences of the National Uni-
versity of La Plata were included in the experience. Mice 
were weighed at the beginning of experiment and each day 
until the end of the experiment. Animals were sacrificed at 
day 37 because at this stage of the study the tumor begins to 
ulcerate and become severely infected. 
Breeding conditions: mice were subjected to the fol-
lowing standard conditions: water and food available ad 
libitum, ambient temperature maintained at 22±2°C, alter-
nating light and dark periods restricted to 12 h each with 
illumination by fluorescent lamps beginning at 06:00 a.m.11 
Tumor Cell Line: After an appropriate period of syn-
chronization, the C3H/S-breast adenocarcinoma labeled 
as TN60-UNLP-C3H/S, was grafted into the subcutaneous 
tissue of each animal’s flank. This is a breast carcinoma that 
was spontaneously originated in January 2003 in a C3HS 
mouse of 16 months of age and it is currently in its passage 
number 131. Macroscopically, it is a well-defined tumor, of 
yellowish color and elastic consistency. Morphologically, it 
is categorized as a solid neoplasm encapsulated with cells of 
medium to large size, vesicular nuclei with prominent nu-
cleoli, scarce basophilic cytoplasm and abundant figures of 
mitosis and apoptotic forms. It is considered an aggressive 
tumor that ulcerates after 37 days and causes the death of 
the specimens affected at day 40 in average. The dose of the 
tumor injected subcutaneously on the flank of each mouse 
was 4×105 cells.
Peptide synthesis and sequence: Peptide was synthe-
sized in an automated multiple peptide synthesizer with 
solid phase procedure and standard Fmoc chemistry by 
the company GL Biochem Ltd, Shanghai, China. The pu-
rity and composition of the peptides were confirmed by 
reverse phase HPLC and by mass spectrometry. The se-
quence of the peptide Mut3DPT-PP2A/SET is as follow: 
VKKKKIKAEIKI ETVTLLVALKVRYRERIT. The sequence 
VKKKKIKAEIKI corresponds to the cell penetrating pep-
tide and the sequence ETVTLLVALKVRYRERIT corre-
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sponds to the interfering peptide blocking the interaction 
between PP2A and SET.
Experimental groups
The graft-bearing animals were divided into 2 groups: 
group 1 (control): injected with saline buffer and group 2 
injected intraperitoneally with the Mut3DPT-PP2A/SET 
peptide (5 mg/kg) every day from day 5 to day 37. 
Variables
Tumor size and histological changes in optical microscop-
ic analysis were selected as variables. Tumor growth was 
measured in mm (length×width), on alternate days, since 
the moment they become visible macroscopically until 
30 days post tumor graft. Histological changes in tissue 
samples were performed after the sacrifice of the animals 
at day 37. The anatomopathological analysis consisted in 
a Hematoxylin and Eosin staining process. For determi-
nation of morphometric parameters, a digital image ana-
lyzer was used. Colored sections were observed under an 
optical microscope (Olympus BX-50, Tokyo, Japan) and 
the selected images were captured by a digital video cam-
era and entered into a computer for quantitative analysis by 
ImagePro / ImageJ (NIH-USA)
Statistical analysis
The data were statistically analyzed using ANOVA and 
Student-Keuls Multiple Comparisons test and Tuckey as a 
post-test.
Ethical considerations
Conditions concerning animal management fully respect-
ed the policy and mandates of the Guide for the Care and 
Use of Laboratory Animal Research of the National Re-
search Council. We obtained the X±ES of each experimen-
tal group. 
RESULTS
After the tumor graft, 48 mice were randomized and as-
signed to the two study groups: 24 specimens were includ-
ed in the group 1 (controls) and 24 – in group 2 (the treat-
ment group). All mice were injected at day 5 either with 
placebo or with peptide. As we can see in Fig. 1 all animals 
(Group 1 control and Group 2 treated mice) showed the 
appearance of the tumor at approximately day 13 of the tu-
mor graft.
Group 1 (controls mice) grew up faster and had a final 
size greater than that of group 2. However, we couldn’t find 
statistically significant differences between the size of the 
tumors of groups (p.0.07). 
Peptide Mut3DPT-PP2A/SET has anti-tumoral effect 
in human xenograft models of breast cancer.
The in vivo efficacy of the peptide was evaluated in breast 
cancer xenograft models, made using the cell line C3H/S-
UNLP. After the tumor graft, 48 mice were randomized and 
assigned to the two study groups: 24 specimens were in-
cluded in the control group and 24 in the treatment group. 
All mice were injected at day 5 either with placebo or with 
peptide Mut3DPT-PP2A/SET at 5 mg/kg daily in preven-
tive treatment. As shown in Fig. 1, the treated group show 
a strong delay in the tumor development when compared 
to non-treated control group. This tumor reduction was 
round 72%, being statistically significant in comparison 
with controls (p<0.07). Non-treated controls mice were 
sacrificed on day 35.
C3H/S strain mice were subcutaneously inoculated with 
10×106 C3H/S UNLP tumor cells and intraperitoneally (IP) 
treated with 5 mg/kg of the peptide Mut3DPT-PP2A/SET 
Figure 1. Tumor growth by study groups. Tumor growth (TS) was assessed by size calculated by the following formula: 
TS= length × width (mm). All animals were sacrificed at day 37.
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daily. Control mice received NaCl. The average tumor vol-
ume of each group (24 mice per group) is shown in Fig. 1.
Tumor samples were histologically analyzed at day 37. 
Figs 2, 4 shows the histological status of the tumor in con-
trol group at different magnification and Figs 3, 5 – the ef-
fect of peptide treatment.
It is clear that in the tumor samples from control group 
there shows a higher degree of inflammation, apoptosis and 
necrosis compared to the treated group either at ×10 or ×40 
magnification.
The tumor showed an expansive growth, with intense 
reddish coloration and central necrotic changes when 
treated with peptides. Histological analysis demonstrated 
a solid neoplasm composed of medium to large cells with 
vesicular nuclei and prominent nucleoli, with scarce ba-
sophilic cytoplasm and a large amount apoptotic forms in 
treated group.
DISCUSSION
Apoptosis is a genetically programmed cell death proce-
dure and its deregulation is associated among many malig-
nancies including breast cancer. Apoptosis is known to rely 
on the Bcl-2 family members and caspases, however recent 
data suggested that two major families of serine/threonine 
phosphatases, PP1 and PP2A, are key factors involved in 
the cell life or cell death decision.12-14 The Ser/Thre phos-
phatase PP2A has been implicated in both, induction and 
prevention of apoptosis, pointing to a complex interplay of 
phosphatase actions.15 The only clinical drugs that target 
a phosphatase are the immunosuppressive cyclosporine A 
and FK506.16 
Cell penetrating peptides (CPP) are either protein de-
rived or artificially designed amino acid sequences with the 
ability to pass through cellular membranes and deliver dif-
ferent types of cargo.17 CPP can translocate into cells with-
out causing membrane damage, leading to their proposed 
use as vectors for delivering therapeutic cargo.18 Hence, 
they have been applied from cell cultures to organisms with 
therapeutic purpose.19 
Hence, peptides that penetrate cells have emerged as 
new modulators of protein-protein interactions that allow 
the delivery of biomolecules through biological barriers, 
thus overcoming the obstacles of internalization and deliv-
ery of these vectors to cells. A promising therapeutic use 
of these biomolecules are testing bi-functional peptides 
with penetration capability and protein/protein interfering 
properties like DPT-C9h20, targeted to the binding site of 
caspase-9 to PP2A. This type of peptides, has the ability 
to induce apoptosis in vitro. Since PP2A has been charac-
terized as a tumor suppressor, the inhibition of PP2A ac-
tivity increases tumorigenesis, and its modulation can be 
beneficial for cancer treatment21-22, suggesting that this 
protein can be considered as a therapeutic target. In the 
last years, several cellular inhibitory proteins of PP2A have 
been described, but one of the more exciting is the SET on-
Figure 2. Tumor sample from control mice at day 37 (×10).
Figure 3. Tumor sample from Treatment Group at day 37 (×10).
Figure 4. Tumor sample from control mice at day 37 (×40).
Figure 5. Tumor sample from Treatment Group at day 37 (×40).
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coprotein, which contributes to tumorigenesis, by forming 
an inhibitory protein complex with PP2A.23,24 These SET 
oncoproteins are present as endogenous inhibitors PP2A 
and cancerous inhibitor of PP2A (CIP2A) that are in about 
90% of breast cancers.25 That is the reason we focused on 
assaying peptides like Mut3DPT-PP2A/SET containing se-
quences as ETVTLLVALKVRYRERIT, with the capability 
to block the interaction between PP2A and SET. 
The pro-apoptotic peptide we tested in this study spe-
cifically deregulates the interaction between caspase-9 and 
PP2A,20,26,27 which becomes specifically interesting in ag-
gressive breast cancer like UNLP-breast tumor line. The 
anti-neoplastic action was clearly demonstrated in the his-
tological analysis that showed high level of tissue inflam-
mation, apoptosis and necrosis of tumor images, as well as 
a reduction in tumor size when compared with non-treated 
mice of control group. These results give expectations for 
the study of highly aggressive tumors with expression of 
SET oncoproteins.
CONCLUSION
Tumor growth and its evolution are complex phenomenon 
controlled by an intricate pattern of competing processes. 
Classical anti-neoplastic drug chemotherapy seems to reach 
its maximum profit. New therapeutic options are needed to 
obtain better results in the future. In this order, we tested a 
cell penetrating peptide Mut3DPT-PP2A/SET in a breast 
cancer xenograft model. The results of the study showed a 
significant tumor reduction and also several changes in the 
tumor histological analysis. We concluded that the peptide 
Mut3DPT-PP2A/SET has demonstrated anti-tumor activi-
ty by reduction in vivo tumor growth, suggesting the poten-
tial of this peptide as anti-cancer therapeutic agent. 
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Абстракт
Цель: Исследовать клеточно-проникающий и интерферирующий пептид Mut3DPT-PP2A / SET при взаимодействии се-
рин-треонинфосфатазы (PP2A) и его физиологического ингибитора, онкопротеина SET.
Материалы и методы: Взрослым самцам мышей линии C3H / S в возрасте 60 дней вводили суспензию, содержащую клетки 
аденокарциномы молочной железы (TN60) в подкожную клетчатку. Пептид Mut3DPT-PP2A / SET использовали для блокиро-
вания взаимодействия PP2A и онкопротеина SET. Животные были разделены на контрольную группу (инъецированную соле-
вым буфером) и группу вмешательства, которой внутрибрюшинно вводили пептид Mut3DPT-PP2A / SET (5 мг / кг) ежедневно 
с 5 по 37 день. Переменные, использованные для сравнения результата в обеих группах были: размер опухоли в мм. (длина х 
ширина) и гистологические изменения. Для статистического анализа мы использовали тест ANOVA и тест множественных 
сравнений Student-Keuls  и Tuckey для послетестового.
Результаты: 48 мышам была введена суспензия в день 0 с опухолевыми клетками UNLP-C3H / S из молочной железы и после 
рандомизированного отбора их разделили на две группы. На 5-й день всем мышам вводили либо плацебо, либо пептид. Обра-
ботанная группа показала значительное уменьшение опухоли (p.0.07). Гистологические изменения выявили наличие апоптоза 
и некроза опухоли в обработанной группе.
Выводы: Пептид Mut3DPT-PP2A / SET демонстрирует противоопухолевую активность, уменьшая рост опухоли in vivo, что 
представляет собой многообещающее будущее для противоопухолевой терапии.
Ключевые слова 
апоптоз, лекарственное исследование, пептид, рак
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phoma: a predictor of aggressive disease and a new treatment target. 
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